Graeme Bell
Chief Executive Officer at Valo Health, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Judy Lewent | F | 75 |
Valo Health LLC
 Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA.
Valo Health, Inc.
 Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | 31 years |
| José Eduardo Vidal | M | - |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 years |
| Frank Verwiel | M | 62 | 7 years | |
| Margaret M. Madden | F | - | 8 years | |
| William Michael Rosellini | M | 44 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 5 years |
| Douglas Giordano | M | 61 | 8 years | |
| Tom Glocer | M | 63 | 17 years | |
| Hilary Malone | M | 59 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 4 years |
| P. Smalley | M | - |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 3 years |
| Harsha Ramalingam | M | 65 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | - |
| Michael A. Caligiuri | M | 68 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 5 years |
| Dalton Smart | M | 58 | 15 years | |
| Paul Biondi | M | 54 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA.
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | - |
| David Epstein | M | 62 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 5 years |
| Richard T. Santulli | M | - |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | - |
| Jorge Conde | M | 47 |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 years |
| Garry Nicholson | M | 69 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 years |
| Akiko Miyashita | F | 68 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 5 years |
| Douglas Williams | M | 66 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 years |
| Sanat Chattopadhyay | M | - | 15 years | |
| Pamela Eisele | F | - | 15 years | |
| Shreeram Aradhye | M | 62 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | - |
| Denise Williams | F | - | 15 years | |
| Brett Chugg | M | 56 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | - |
| Bryan Supran | M | - | 8 years | |
| Patrick M. Gray | M | 75 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Berry | M | 47 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 6 years |
| Paul Berns | M | 57 | 4 years | |
| Nessan Bermingham | M | 51 | 3 years | |
| Christina Coughlin | M | 54 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 4 years |
| Mark Leschly | M | 55 | 14 years | |
| Lucy Shapiro | M | 83 | 16 years | |
| Fred Hassan | M | 78 | 6 years | |
| Kenneth Bartizal | M | 72 | 20 years | |
| William Rieflin | M | 64 | 5 years | |
| Ismail Kola | M | 67 | 4 years | |
| Wendy Yarno | F | 69 | 9 years | |
| Keith Leonard | M | 62 | 2 years | |
| Robert Iannone | M | 57 | 6 years | |
| Lucy Day | F | 65 | 14 years | |
| Ryan Sullivan | M | 48 | 2 years | |
| Carlos Eduardo Represas de Almeida | M | 78 | - | |
| Mojirade James | F | 57 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 3 years |
| Craig Thompson | M | 71 | 10 years | |
| Jean-Marie Canan | M | 68 | 5 years | |
| Carl Gordon | M | 59 | 2 years | |
| Thomas Robert Cech | M | 76 | - | |
| David Anstice | M | 75 | 5 years | |
| Leslie Brun | M | 72 | 13 years | |
| Andrew Schiermeier | M | 54 | 3 years | |
| Richard Henriques | M | 68 | 27 years | |
| William N. Kelley | M | 84 | - | |
| Anders Hove | M | 58 | 11 years | |
| Harry R. Jacobson | M | 76 | 3 years | |
| Wendell Wierenga | M | 76 | 2 years | |
| Caroline Dorsa | F | 64 | 22 years | |
| Bruno Strigini | M | 63 | 5 years | |
| Richard Pasternak | M | 75 | 4 years | |
| Eric Schadt | M | 59 | 8 years | |
| Erin McClain | F | - | - | |
| Glenn Williams | M | - | 10 years | |
| Franklin Clyburn | M | 59 | 13 years | |
| Maude Tessier | M | 46 | 6 years | |
| D. Gilliland | M | 69 | 4 years | |
| Jason Pesile | M | 50 | 2 years | |
| Lu Amy Sun | M | 67 | 7 years | |
| Alexis Ji | M | - | 5 years | |
| Rafael Torgovicky | M | - | 2 years | |
| Sheldon Koenig | M | 58 | 6 years | |
| Yao Lee | M | 54 | 3 years | |
| Mark Shearman | M | 62 | 3 years | |
| Stephen Farrand | M | - | 6 years | |
| Benito Munoz | M | 62 | 9 years | |
| Aaron Dent | M | - | 6 years | |
| Adele D. Ambrose | F | 67 | - | |
| Silvana Battaglia | F | 56 | 10 years | |
| Chandra Vargeese | M | 63 | 1 years | |
| Stanley F. Barshay | M | 83 | 1 years | |
| Raul E. Kohan | M | 71 | 1 years | |
| Peter Kim | M | 65 | 5 years | |
| Stefan Oschmann | M | 66 | 20 years | |
| Angelique M. Carbo | F | 59 | 2 years | |
| William G. Bowen | M | 90 | 21 years | |
| Margaret McGlynn | F | 64 | 11 years | |
| Peter Kellogg | M | 67 | 7 years | |
| Peter D. Löscher | M | 66 | 1 years | |
| Dennis Erb | M | - | - | |
| Steven Kelmar | M | 70 | 3 years | |
| Lawrence D. Senour | M | 59 | - | |
| David Monteith | M | 60 | 5 years | |
| Mervyn Turner | M | 77 | 2 years | |
| Raymond F. Kerins | M | - | 1 years | |
| Janelle Anderson | M | 51 | 6 years | |
| François Martelet | M | 64 | 2 years | |
| Christopher Garland | M | - | - | |
| Ray Hill | M | 79 | 18 years | |
| Sandy Matalonis | F | - |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 1 years |
| Mark Stejbach | M | 61 | 21 years | |
| Piotr Bobrowicz | M | - | - | |
| David Parry | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Graeme Bell
- Personal Network
